A federal judge in the District of Delaware ruled in favor of Finnegan client Forest Laboratories in a Hatch-Waxman litigation against Mylan Inc. Mylan was found to infringe three patents held by Forest, following its attempt to create a generic version of Savella, Forest's drug treatment for fibromyalgia. The validity of the three asserted patents was also confirmed.